Clinical Trial Update: Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 clinical trial evaluated neoadjuvant cetuximab-based chemotherapy (Erbitux) for locally advanced oral and oropharyngeal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Cancer
• Oropharyngeal Cancer

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

Sponsor: Shanghai Jiao Tong University School of Medicine | Conditions: Locally Advanced Malignant Neoplasm, Oral Cancer | Phase 2, Phase 3 | Status: COMPLETED